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Abstract 
Mesenchymal stem cells are adult non-hematopoietic stem cells with multilineage proliferation 
and differentiation capabilities. This type of stem cell has the multipotent ability to differentiate 
into osteocytes, tenocytes, adipocytes, chondrocytes and  bone marrow stromal cells. The 
migration mechanism of mesenchymal stem cell is not yet fully understood, but based on 
studies  that  have  been  done  recently  by  the  researchers  worldwide  shown  that  the 
inflammatory process plays an important role for mesenchymal stem cell migration. A number 
of chemokine that plays a role in the migration of mesenchymal stem cells such as MCP-1 
(CCL2), CXCL8, RANTES (CCL5), LL-37, integrin β1, CD44 receptor, CCR2, CCR3, and tyrosine 
kinase receptors for the following growth factors: IGF -1, PDGF-bb, HGF and VEGF. 
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Introduction 
Stem cells are cells that became the beginning of the growth of other cells that made the whole of the 
body of an organism. To be classified as a stem cell, a cell must have a number of characteristics such 
as undifferentiated, self-renewal and able to differentiate  into more than one type of cells (multi 
potent/pluripotent) (Halim et al., 2010). Based on the degree of body maturation of the source of its 
existence,  practically  stem  cell  is  divided  into  two  types:  embryonic  stem  cells and adult  stem 
cells. Embryonic stem cells are obtained during embryonic stage of individual’s development. In the 
next development stage, these cells will differentiate more mature which has the lower capability of 
proliferation  and  differentiation  than  embryonic  stem  cells. Embryonic  stem  cells  are  classified 
as pluripotent stem cells which can be used as a treatment for almost all degenerative diseases (Halim 
et al., 2010). Stem cell/progenitor cell can only perform differentiation and proliferation if supported 
by appropriate  microenvironment  for its  maturation  process.  Microenvironment (niche) involves  a 
series  of  supporting  cells,  cytokines, signaling pathways  and  cell  adhesion  molecules. Stem  cells 
migration process requires a substance that can break the bonds between the stem cell with cell 
adhesion molecules in the matrix (Rettig et al., 2012 ; Ratajzak et al., 2012). 
 
There are several types of bonds which maintain the stem cell remain in the matrix such as kit with kit 
ligand, CD44 with hyaluronic acid, CD62 with PSGL, VLA4 with VCAM-1 and CXCR4 with SDF 1. This 
bond will detach when exposed to cytokines or subcellular protein as a result of the inflammatory 
process and ischemia such as IL-8 and norepinephrine. Furthermore, the detach stem cells migrate 
according certain signal found during the process. Some studies have suggested that some molecules 
can act as chemoattractan such as VEGF, CXCL12, IL-6, MMIF, Integrins and PDGF. With the signals 
given by a substance  that acts as chemoattractan the stem cells/progenitor  will mobilize  to the 
location of the source of the chemoattractan and will ultimately perform homing on the site to further 
develop into cells corresponding to the stimulus it receives (Ratajzak et al., 2012 ; Rettig et al., 
2012). Mesenchymal stem cell is type of adult stem cells which is most widely researched and 
clinically tested. This type of stem cell has the multipotent  ability and able to differentiate  into 
osteocytes, tenocytes, adipocytes, chondrocytes and bone marrow stromal cells. The  Mechanism of 
mesenchymal stem cell’s migration/homing is not yet fully understood. However, the inflammatory 
process is believed to have an important role on the mechanisms of mesenchymal stem cell migration. 
 
 
Materials and Methods 
Data shown in this article refers to a number of worldwide research. Table 1 only provide data about a 
number  of  receptors  expressed  on  mesenchymal  stem  cells  which  has  been  known  to  have 
implications in cell migration. The selection of this data is used to facilitate a better understanding of 
the reader regarding the mesenchymal stem cells migration (Spaeth et al., 2008). 
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Results and Discussion 
Mesenchymal stem cells are adult non-hematopoeietik stem cells with multilineage proliferation and 
differentiation capabilities. Mesenchymal stem cells plays a role in the maintenance and regeneration 
of connective tissue and has the ability to differentiate into osteoblasts, adipocytes, chondrocytes, 
myocytes, and cardiomyocytes. Marker expressed by mesenchymal stem cells include CD29, CD44, 
CD51, CD73 (SH3/4), CD105 (SH2), CD166 (Alcam) and stro-1. In order to express a specific marker 
combination by mesenchymal stem cells is highly dependent on the microenvironment ( Spaeth et al., 
2008 ; Zappia et al., 2005 ). Theoretically, mesenchymal stem cells found in all organs of the human 
body, more precisely as a part of the population of cells contained in the perivascular region. According 
to the number of cells, accessibility and previous research, there are three most widely used sources to 
obtain mesenchymal stem cells: bone marrow, cord blood and adipose tissue (Halim et al., 2010 ). 
 
The number of mesenchymal stem cells present in adipose tissue more than mesenchymal stem cells 
from  two  other  sources  (bone  marrow  and  cord  blood). The  scientific  literature  states  that  the 
percentage of mesenchymal stem cell isolation from adipose tissue is equal with the bone marrow, 
which is 100%. Isolation of mesenchymal stem cells from umbilical cord blood is very difficult to do, 
this condition result in 29-63% success rate of mesenchymal stem cell from this source. Nonetheless, 
mesenchymal stem cells obtained from umbilical cord blood have much higher proliferation potential 
than bone marrow (Halim et al., 2010 ). 
 
To date, the absolute characteristics of mesenchymal stem cells is still widely questioned, especially 
regarding its surface protein molecule. As an example of this discrepancy is the presence of CD29, 
CD44 and CD166 which are actually also can be found  in mesenchymal  stem cells. In addition, 
mesenchymal stem cells isolated from adipose tissue also showed expression of CD34 and CD54 on its 
surface. In terms of differentiation potential, a number of researchers also reported that mesenchymal 
stem cells obtained from umbilical cord blood are only able to form in two lines of differentiation: 
chondrogenic and osteogenic (Halim et al., 2010 ). 
 
In accordance with the consensus issued by the International Society of Cellular Therapy, a cell that 
categorized as mesenchymal stem cells must have the following characteristics: 
      The cells will attach to the surface of the dish when cultured in a plastic culture dish. 
 Has  a  surface  protein  molecules (Cluster of  Differentiation, CD): CD73,  CD90,  and  CD105. In 
contrast to hematopoietic stem cells, mesenchymal stem cells do not express CD34, CD214, 
CD45 and HLA-DR. 
      Able  to  differentiate  into  three  main  lines  of  mesenchymal  differentiation:  the  osteogenic 
(becoming   bone  cells/osteocytes),   chondrogenic   (becoming   chondrocytes   cartilages)   and 
adipogenic (becoming fat cells/adipocytes) (Halim et al., 2010). 
 
The bone marrow-derived mesenchymal stem cells has been used in engrafment hematopoietic stem 
cell transplantation  which was performed  after chemotherapy  to restore  the population  of bone 
marrow cells. Mesenchymal stem cells are also has been used to reduce graft-versus-host disease, 
tissue  repair  including  cerebral  injuries,  bone fractures,  ischemia/myocardial  infarction,  muscular 
dystrophy, and also to homing tumor (Spaeth et al., 2008; Lopez et al., 2007). Mesenchymal stem 
cells are believed to have chemotactic device similar to other immune cells that provide a response to 
injury and inflammation location. Inflammation is a cellular response that appears on the condition of 
cellular injury and the scar tissue. One example of ongoing inflammatory condition is a tumor, and this 
disease is the target of mesenchymal stem cells. More than two decades ago, Dvorak and colleagues 
have explained that the tumor act as an 'unheal wound” which produce inflammatory mediators 
sources  continuously  (such  as  cytokine,  chemokine  and  other  chemoattractant  molecules). The 
production of these inflammatory mediators (which are constantly occur) will lead to the continuity of 
maintenance and development mechanisms of tumour microenvironent, this mechanism is the target 
of mesenchymal stem cells (Spaeth et al., 2008). 
 
Inflammatory mediators plays a role in determining the microenvironment conditions, such as its role 
in regulating the invasion, motility, extracellular matrix interactions through autocrine effects, also in 
coordinating the movement of cells through paracrine signaling (Spaeth et al., 2008). Inflammatory 
chemokynes  produced  by  a  tumour  known  to  have  an  important  role  in  the  infiltration  of 
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leukocytes/macrophages to the tumour. Based on this evidence, it can be speculated that the 
chemokine-induced inflammation participates in directing migration/mobilization of stem cells, such as 
mesenchymal stem cells. A number of previous studies have shown the importance of inflammation to 
the success of the homing mechanism of hematopoietic stem cell infused into the heart tissue, this 
fact  reinforces  the  idea  of  inflammatory  and  chemokine  production  in  mesenchymal  stem  cell 
migration (Spaeth et al., 2008). Inflammatory conditions has a number of similarities with hypoxia, 
one of which is the expression of the pro-angiogenic molecules. Induction of transcription factor HIF- 
1α activates transcription of genes including vascular endothelial growth factor (VEGF), macrophage 
migration inhibitory factor, tumor necrosis factor (TNF-α), a number of proinflammatory cytokines and 
activation of the transcription factor nuclear factor κB (Spaeth et al., 2008; Winner et al., 2007). 
 
Nuclear factor κB often activated as a response to inflammatory mediators and it has been proved to 
induce a number of ckemokines (RANTES (CCL5), MIP-2 (CXCL2), MIP-1α (CCL3), monocyte 
chemoattractant protein 1 (MCP-1) (CCL2), interleukin-8 (CXCL8)), which are involved in leukocyte 
migration  process  (Spaeth  et  al.,  2008;  Pold  et  al.,  2004).  Mesenchymal  stem  cell  migration 
mechanism is not fully understood until now and its still under investigation. However, the factors that 
are involved in regulating leukocyte migration process has been studied extensively and it seems 
there are a lot of the same factors that are involved in the regulation of mesenchymal stem cell 
migration (Spaeth et al., 2008). A number of receptors expressed on mesenchymal stem cells and has 
been known to have implications in cell migration can be seen in the following table: 
 
Table 1. Mesenchymal stem cells’ surface markers and its receptors related to cell 
migration (Spaeth et al., 2008) 
 
 Cell surface 
receptors found 
on MSC 
 
Ligands Present on other cell 
types 
 
 
 
 
Growth 
hormone 
receptors 
EGFR (ErbB) EGF DC, neutrophil 
HGFR (c-met) HGF Leukocytes, 
macrophages 
IGFIR IGF1 Leukocytes, HSC 
PDGFR (Ra-b) PDGFa/b HSC 
VEGFR1 VEGF HSC, monocytes, 
neutrophils 
VEGFR2 VEGF HSC 
FGFR2 FGF2 HSC, leukocytes 
Tie-2 Ang-1 HSC, leukocytes 
 
 
 
 
 
 
 
 
 
 
 
 
Chemokine / 
cytokine 
receptors 
CCR1 CCL3, CCL5, CCL7, CCL13, CCL14, 
CCL15, CCL16, CCL23 Monocyte, T cell, DC 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 Monocyte, T cell, DC 
CCR3 CCL5, CCL7, CCL8, CCL11, CCL13, 
CCL15, CCL16, CCL24, CCL26, CCL28 T cell, DC 
CCR4 CCL17, CCL22 T cell, macrophage, DC 
CCR5 CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, 
CCL16 
Monocyte, T cell, DC, 
HSC 
CCR6 CCL20 T cell, B cell, DC 
CCR7 CCL19, CCL21 T cell, DC 
CCR8 CCL1 Monocyte, T cell, DC 
CCR9 CCL25 T cell 
CCR10 CCL27, CCL28 T cell 
CXCR1 CXCL6, CXCL7, CXCL8 Neutrophil, monocyte 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7, CXCL8 Neutrophil, monocyte 
CXCR3-A/B CXCL4, CXCL9, CXCL10, CXCL11 T cell, microvascular 
cells 
 
CXCR4 
 
CXCL12 
T cell, B cell, 
monocyte, 
macrophage, DC 
CXCR5 CXCL13 B cell, Th cells, HSC 
CXCR6 CXCL16 CD8 T cells, NK cells, 
CD4 T cells 
CX3CR1 CX3CL1 Macrophage 
XCR1 XCL1, XCL2 T cell, NK cell 
Adhesion VCAM-1 (VLA-4) β1 integrin/α4 integrin Leukocytes 
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Molecules ICAM-1/3 LFA-1 Leukocytes, DC 
ALCAM CD6 Leukocytes 
Endoglin (CD105) TGF β1/3 Leukocytes, HSC 
TLR1 Lipopeptides Leukocytes 
 
Innate 
immune 
surveillance 
TLR2 Peptidoglycans, lipopeptides Monocytes, DC 
TLR3 dsRNA DC 
TLR4 LPS Monocytes, DC 
TLR5 ECM molecules Monocytes 
TLR6 Peptidoglycans Epithelium 
 
Activation of mesenchymal stem cells with proinflammatory cytokines (TNF-α) before reinfusion has 
been   proven   in   vivo   able   to   increase   mesenchymal   stem   cell   migration   and   adhesion 
capacity (adherence) through  the  increase  of receptor’s  expression. Existing  data  stating  that  the 
cytokine IL-1β and TNF-α activating adherence devices owned by mesenchymal stem cells include 
upregulation of adhesion pathway of VCAM-1 VLA-4. Other receptors which undergo upregulation by 
TNF-α include CCR3 and CCR4; These findings relate to the in vitro observations to the increased 
migration to RANTES (a CCR3 ligand) and macrophage-derived cytokines (MDC (CCL22)-ligand CCR4) 
(Spaeth et al., 2008; Segers et al., 2006; Lopez et al., 2007). 
 
Inflammatory chemokine receptor expression in mesenchymal stem cell are affected by the condition 
of micronvironment. For example, TNF-α causes upregulation chemokine receptors CC- but not on 
CXC-. The existence of certain chemokine receptor upregulation in response to cellular signals may 
have a role in tissue-specific homing (Lopez et al., 2007; Spaeth et al., 2008). 
 
Conclusions 
Mesenchymal stem cell is type of adult stem cells which is most widely researched and clinically 
tested. This   type   of  stem   cell  has   the   multipotent   ability   and   able   to  differentiate   into 
osteocytes, tenocytes, adipocytes, chondrocytes and bone marrow stromal cells. Marker expressed by 
mesenchymal stem cells include CD29, CD44, CD51, CD73 (SH3/4), CD105 (SH2), CD166 (Alcam) 
and stro-1. In order to express a specific marker combination by mesenchymal stem cells is highly 
dependent on the microenvironment. Mesenchymal stem cells are believed to have chemotactic device 
similar to other immune cells that provide a response to injury and inflammation location. A number of 
chemokine that plays a role in the migration of mesenchymal stem cells such as MCP-1 (CCL2), 
CXCL8,  RANTES  (CCL5),  LL-37,  integrin  β1,  CD44  receptor,  CCR2,  CCR3,  and  tyrosine  kinase 
receptors for the following growth factors: IGF -1, PDGF-bb, HGF and VEGF. Further research should 
be conducted to explore the mechanism of mesenchymal stem cells migration. 
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